连续性肾替代治疗抗菌药物剂量调整共识专家组 中国药学会医院药学专业委员会 中国医药教育协会感染疾病专业委员会 通信作者:卢晓阳,浙江大学医学院附属第一医院临床药学部,杭州 310003,Email:luxiaoyang@zju.edu.cn;蔡洪流,浙江大学医学院附属第一医院重症医学科,杭州 310003,Email:1193001@zju.edu.cn 一、共识形成方法二、CRRT因素对CRRT中抗菌药物剂量的影响
(一) CRRT模式(二) CRRT滤器(三) 置换液补充形式与CRRT治疗剂量三、药物特性对CRRT中抗菌药物剂量的影响
四、患者因素对CRRT中抗菌药物剂量的影响
五、CRRT期间各类抗菌药物使用基本原则(一)抗细菌药物
2. 氨基糖苷类抗菌药物: 3. 喹诺酮类抗菌药物:
4. 糖肽类抗菌药物:
5. 环脂肽类抗菌药物:
6. 噁唑烷酮类抗菌药物: 7. 替加环素: 8. 多黏菌素类抗菌药物: 9. 磺胺类抗菌药物: (二)抗真菌药物1. 唑类抗真菌药物: 2. 棘白菌素类抗真菌药物: 3. 多烯类抗真菌药物: 六、CRRT特殊情况下抗菌药物调整策略声明 编制本共识时邀请了药学专家及各相关学科临床专家对所有数据进行了审议。但是由于此类数据可能会随时发生变化,因此我们无法确保其在使用时的准确性,医师应根据其专业知识负责解释和应用所有数据。出版方不对在本文件指导下做出的任何医疗卫生行为承担任何法律责任,也不对未经授权使用本文件的任何其他使用方承担任何法律责任 志谢 感谢以下专家在共识制定中的帮助(按姓名汉语拼音字母表顺序排序):曹恒斌(湖州市中心医院)、戴单单(宁波大学附属第一医院)、胡阳敏(浙江大学医学院附属第二医院)、李晴宇(杭州市肿瘤医院)、林彬(长兴县人民医院)、芦小燕(宁波华美医院)、毛小红(浙江省人民医院)、吴娇芬(宁波市医疗中心李惠利医院)、项迎春(浙江医院)、俞振伟(浙江大学医学院附属邵逸夫医院)、詹海潮(金华市中心医院)、张春红(温州大学医学院附属第一医院)、张萍(浙江大学医学院附属第一医院)、郑霞(浙江大学医学院附属第一医院)、周志慧(浙江大学医学院附属邵逸夫医院)、朱剑萍(浙江大学医学院附属邵逸夫医院)利益冲突 所有作者声明无利益冲突1. 国家卫生健康委办公厅. 关于印发血液净化标准操作规程(2021版)的通知[EB/OL]. (2021-11-09)[2023-04-03]. http://www./cms-search/xxgk/getManuscript Xxgk.htm?id=6e25b8260b214c55886d6f0512c1e53f. 2. Deepa C, Muralidhar K. Renal replacement therapy in ICU[J]. J Anaesthesiol Clin Pharmacol, 2012, 28(3): 386-396. DOI: 10.4103/0970-9185.98357. 3. Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis[J]. Intensive Care Med, 2017, 43(6): 816-828. DOI: 10.1007/s00134-017-4755-7. 4. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study[J]. JAMA, 2005, 294(7): 813-818. DOI: 10.1001/jama. 294.7.813. 5. Roberts JA, Joynt GM, Lee A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study[J]. Clin Infect Dis, 2021, 72(8): 1369-1378. DOI: 10.1093/cid/ciaa224. 6. Kanji S, Roger C, Taccone FS, et al. Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy[J]. Pharmacotherapy, 2023, 43(11): 1194-1205. DOI: 10. 1002/phar.2858. 7. Hoff BM, Maker JH, Dager WE, et al. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update[J]. Ann Pharmacother, 2020, 54(1): 43-55. DOI: 10.1177/1060028019865873. 8. Wong WT, Choi G, Gomersall CD, et al. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt[J]. Curr Opin Pharmacol, 2015, 24: 68-78. DOI: 10. 1016/j.coph.2015.07.003. 9. Corona A, Veronese A, Santini S, et al. 'CATCH' study: correct antibiotic therapy in continuous hemofiltration in the critically ill in continuous renal replacement therapy: a prospective observational study[J]. Antibiotics (Basel), 2022, 11(12): 1811. DOI: 10.3390/antibiotics11121811. 10. Onichimowski D, Ziółkowski H, Nosek K, et al. Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies[J]. J Artif Organs, 2020, 23(2): 163-170. DOI: 10.1007/s10047-019-01139-x. 11. Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, et al. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements[J]. J Antimicrob Chemother, 2016, 71(6): 1651-1659. DOI: 10.1093/jac/dkv503. 12. Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how[J]. Chest, 2019, 155(3): 626-638. DOI: 10.1016/j.chest.2018.09.004. 13. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11): 825-830. DOI: 10.7326/0003-4819-158-11-201306040- 00007. 14. Tulli G. Antibiotic dosing during continuous renal replacement therapy (CRRT)[M].//Davide Chiumello. Topicalissues in anesthesia and intensive care. Milano, Italy: Springer International Publishing, 2016: 1-33. 15. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper[J]. Intensive Care Med, 2020, 46(6): 1127-1153. DOI: 10.1007/s00134-020- 06050-1. 16. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)[J]. Pharmacotherapy, 2019, 39(1): 10-39. DOI: 10.1002/phar.2209. 17. Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid[J]. Front Public Health, 2022, 10: 967311. DOI: 10.3389/fpubh.2022.967311. 18. Chen K, Zhang X, Ke X, et al. Individualized Medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674. DOI: 10.1097/FTD.0000000000000561. 19. Dekkers B, Bakker M, van der Elst K, et al. Therapeutic drug monitoring of posaconazole: an update[J]. Curr Fungal Infect Rep, 2016, 10: 51-61. DOI: 10.1007/s12281-016-0255-4. 20. Stevenson JM, Patel JH, Churchwell MD, et al. Ertapenem clearance during modeled continuous renal replacement therapy[J]. Int J Artif Organs, 2008, 31(12): 1027-1034. DOI: 10.1177/039139880803101206. 21. Pistolesi V, Morabito S, Di Mario F, et al. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy[J]. Antimicrob Agents Chemother, 2019, 63(8): e00583-19. DOI: 10. 1128/AAC.00583-19. 22. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions[J]. Lancet Infect Dis, 2014, 14(6): 498-509. DOI: 10.1016/S1473-3099(14)70036-2. 23. Corona A, Cattaneo D, Latronico N. Antibiotic therapy in the critically ill with acute renal failure and renal replacement therapy: a narrative review[J]. Antibiotics (Basel), 2022, 11(12): 1769. DOI: 10.3390/antibiotics 11121769. 24. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy[J]. Clin Infect Dis, 2005, 41(8): 1159-1166. DOI: 10.1086/444500. 25. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis[J]. Pharmacotherapy, 2009, 29(5): 562-577. DOI: 10.1592/phco.29.5.562. 26. Carlier M, Taccone FS, Beumier M, et al. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2015, 46(4): 413-419. DOI: 10.1016/j.ijantimicag.2015.05.020. 27. Sember AM, LoFaso ME, Lewis SJ. Author response: 'an optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy'[J]. J Crit Care, 2022, 70: 154059. DOI: 10.1016/j.jcrc.2022.154059. 28. Jang SM, Lewis SJ, Rhie SJ. Optimal antipseudomonal - lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT[J]. J Crit Care, 2022, 72: 154172. DOI: 10.1016/j.jcrc.2022.154172. 29. Chaijamorn W, Charoensareerat T, Srisawat N, et al. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study[J]. J Intensive Care, 2018, 6: 61. DOI: 10.1186/s40560-018-0330-8. 30. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation[J]. Crit Care, 2006, 10(1): R26. DOI: 10.1186/cc3993. 31. Philpott CD, Droege CA, Droege ME, et al. Pharmacokinetics and pharmacodynamics of extended- infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study[J]. Pharmacotherapy, 2019, 39(11): 1066-1076. DOI: 10.1002/phar.2332. 32. Al-Shaer MH, Philpott CD, Droege CA, et al. Cefepime population pharmacokinetics and target attainment in critically ill patients on continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2021, 65(6): e00144-21. DOI: 10.1128/AAC.00144-21. 33. Goto K, Sato Y, Yasuda N, et al. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy[J]. J Basic Clin Physiol Pharmacol, 2016, 27(6): 625-631. DOI: 10.1515/jbcpp-2016-0022. 34. Roger C, Cotta MO, Muller L, et al. Impact of renal replacement modalities on the clearance of piperacillin- tazobactam administered via continuous infusion in critically ill patients[J]. Int J Antimicrob Agents, 2017, 50(2): 227-231. DOI: 10.1016/j.ijantimicag.2017.03.018. 35. Seyler L, Cotton F, Taccone FS, et al. Recommended β- lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy[J]. Crit Care, 2011, 15(3): R137. DOI: 10.1186/cc10257. 36. Varghese JM, Jarrett P, Boots RJ, et al. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration[J]. Int J Antimicrob Agents, 2014, 43(4): 343-348. DOI: 10.1016/j.ijantimicag.2014.01.009. 37. Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis[J]. J Antimicrob Chemother, 2014, 69(1): 180-189. DOI: 10. 1093/jac/dkt304. 38. Jamal JA, Roberts DM, Udy AA, et al. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration[J]. Int J Antimicrob Agents, 2015, 46(1): 39-44. DOI: 10.1016/j.ijantimicag.2015.02.014. 39. Shotwell MS, Nesbitt R, Madonia PN, et al. Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing CRRT[J]. Clin J Am Soc Nephrol, 2016, 11(8): 1377-1383. DOI: 10.2215/CJN. 10260915. 40. Richter DC, Frey O, Röhr A, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience[J]. Infection, 2019, 47(6): 1001-1011. DOI: 10.1007/s15010-019- 01352-z. 41. Awissi DK, Beauchamp A, Hébert E, et al. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy[J]. Pharmacotherapy, 2015, 35(6): 600-607. DOI: 10.1002/phar.1604. 42. Gao C, Tong J, Yu K, et al. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration[J]. Eur J Clin Pharmacol, 2016, 72(7): 823-830. DOI: 10.1007/s00228- 016-2045-x. 43. Wenzler E, Bunnell KL, Bleasdale SC, et al. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration[J]. Antimicrob Agents Chemother, 2017, 61(7): e00464-17. DOI: 10. 1128/AAC.00464-17. 44. Soukup P, Faust AC, Edpuganti V, et al. Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration[J]. Pharmacotherapy, 2019, 39(12): 1216-1222. DOI: 10. 1002/phar.2338. 45. Zhang XS, Wang YZ, Shi DW, et al. Correction to: efficacy and pharmacodynamic target attainment for ceftazidime- avibactam off-label dose regimens in patients with continuous or intermittent venovenous hemodialysis: two case reports[J]. Infect Dis Ther, 2022, 11(6): 2321. DOI: 10.1007/s40121-022-00675-z. 46. Gatti M, Rinaldi M, Gaibani P, et al. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)[J]. J Crit Care, 2023, 76: 154301. DOI: 10.1016/j.jcrc.2023.154301. 47. Cotton A, Franklin BD, Brett S, et al. Using imipenem and cilastatin during continuous renal replacement therapy[J]. Pharm World Sci, 2005, 27(5): 371-375. DOI: 10.1007/s11096-005-1636-x. 48. Boucher BA, Hudson JQ, Hill DM, et al. Pharmacokinetics of imipenem/cilastatin burn intensive care unit patients undergoing high-dose continuous venovenous hemofiltration[J]. Pharmacotherapy, 2016, 36(12): 1229- 1237. DOI: 10.1002/phar.1866. 49. Li Z, Bai J, Wen A, et al. Pharmacokinetic and pharmacodynamic analysis of critically ill patients undergoing continuous renal replacement therapy with imipenem[J]. Clin Ther, 2020, 42(8): 1564-1577.e8. DOI: 10.1016/j.clinthera.2020.06.010. 50. Li S, Xie F. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2019, 53(1): 98-105. DOI: 10.1016/j.ijantimicag. 2018.10.006. 51. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients[J]. Antimicrob Agents Chemother, 2005, 49(6): 2421-2428. DOI: 10.1128/AAC.49.6.2421-2428.2005. 52. Kawano S, Matsumoto K, Hara R, et al. Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis[J]. J Infect Chemother, 2015, 21(6): 476-478. DOI: 10. 1016/j.jiac.2015.02.011. 53. Grensemann J, Busse D, König C, et al. Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study[J]. Ann Intensive Care, 2020, 10(1): 48. DOI: 10.1186/s13613-020-00666-8. 54. Charoensareerat T, Chaijamorn W, Kerdnimith P, et al. Optimal meropenem dosing regimens in patients undergoing continuous renal replacement therapy: systematic review and Monte Carlo simulations[J]. Blood Purif, 2023, 52(6): 503-515. DOI: 10.1159/000529694. 55. Chaijamorn W, Rungkitwattanakul D, Pattharachayakul S, et al. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy[J]. J Crit Care, 2020, 60: 285-289. DOI: 10.1016/j.jcrc.2020.09.001. 56. Langgartner J, Vasold A, Glück T, et al. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy[J]. Intensive Care Med, 2008, 34(6): 1091-1096. DOI: 10.1007/s00134-008-1034-7. 57. Burger R, Guidi M, Calpini V, et al. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life- threatening infections[J]. J Antimicrob Chemother, 2018, 73(12): 3413-3422. DOI: 10.1093/jac/dky370. 58. Nowak-Kózka I, Polok KJ, Górka J, et al. Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial[J]. Pharmacol Rep, 2020, 72(1): 147-155. DOI: 10.1007/s43440-019-00056-3. 59. Gatti M, Rinaldi M, Tonetti T, et al. Real-time TDM-based expert clinical pharmacological advice program for attaining aggressive pharmacokinetic/pharmacodynamic target of continuous infusion meropenem in the treatment of critically ill patients with documented gram- negative infections undergoing continuous veno-venous hemodiafiltration[J]. Antibiotics (Basel), 2023, 12(10): 1524. DOI: 10.3390/antibiotics12101524. 60. Peng Y, Cheng Z, Xie F. Population pharmacokinetic meta- analysis and dosing recommendation for meropenem in critically ill patients receiving continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2022, 66(9): e0082222. DOI: 10.1128/aac.00822-22. 61. Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2011, 37(6): 531-535. DOI: 10.1016/j.ijantimicag.2011.01.026. 62. Li S, Zhu S, Xie F. Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration[J]. J Pharm Pharmacol, 2023, 75(4): 515-522. DOI: 10.1093/jpp/rgad005. 63. Roger C, Wallis SC, Muller L, et al. Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2016, 60(8): 4901-4909. DOI: 10.1128/AAC. 00828-16. 64. Lam SW, Bauer SR. Amikacin pharmacokinetics during continuous veno-venous hemodialysis[J]. Infect Dis Ther, 2013, 2(2): 217-226. DOI: 10.1007/s40121-013-0012-8. 65. Roger C, Wallis SC, Louart B, et al. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients[J]. J Antimicrob Chemother, 2016, 71(6): 1643-1650. DOI: 10.1093/jac/dkw043. 66. Roehr AC, Frey OR, Koeberer A, et al. Anti-infective drugs during continuous hemodialysis-using the bench to learn what to do at the bedside[J]. Int J Artif Organs, 2015, 38(1): 17-22. DOI: 10.5301/ijao.5000377. 67. Wallis SC, Mullany DV, Lipman J, et al. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno- venous haemodiafiltration[J]. Intensive Care Med, 2001, 27(4): 665-672. DOI: 10.1007/s001340100857. 68. Spooner AM, Deegan C, D'Arcy DM, et al. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration[J]. BMC Clin Pharmacol, 2011, 11: 11. DOI: 10.1186/1472-6904-11-11. 69. Onichimowski D, Wolska J, Ziółkowski H, et al. Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment[J]. Anaesthesiol Intensive Ther, 2020, 52(4): 267-273. DOI: 10.5114/ait.2020.99605. 70. Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients[J]. Antimicrob Agents Chemother, 2001, 45(10): 2949-2954. DOI: 10.1128/AAC.45.10.2949-2954.2001. 71. Shaw AR, Mueller BA. Antibiotic dosing in continuous renal replacement therapy[J]. Adv Chronic Kidney Dis, 2017, 24(4): 219-227. DOI: 10.1053/j.ackd.2017.05.004. 72. Tokimatsu I, Shigemura K, Kotaki T, et al. A prospective study of the efficacy, safety and pharmacokinetics of enteral moxifloxacin in the treatment of hemodialysis patients with pneumonia[J]. Intern Med, 2017, 56(11): 1315-1319. DOI: 10.2169/internalmedicine.56.8369. 73. Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration[J]. J Antimicrob Chemother, 2004, 54(4): 780-784. DOI: 10.1093/jac/dkh421. 74. Omrani AS, Mously A, Cabaluna MP, et al. Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?[J]. Saudi Pharm J, 2015, 23(3): 327-329. DOI: 10.1016/j.jsps.2014. 08.005. 75. Chaijamorn W, Jitsurong A, Wiwattanawongsa K, et al. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients[J]. Int J Antimicrob Agents, 2011, 38(2): 152-156. DOI: 10.1016/j.ijantimicag. 2011.04.010. 76. Li Q, Liang F, Sang L, et al. Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution[J]. Eur J Clin Pharmacol, 2020, 76(2): 211-217. DOI: 10.1007/s00228-019- 02755-5. 77. Wahby KA, Cunmuljaj L, Mouabbi K, et al. Evaluation of dosing strategies and trough concentrations of vancomycin in patients undergoing continuous venovenous hemofiltration[J]. Pharmacotherapy, 2021, 41(7): 554-561. DOI: 10.1002/phar.2535. 78. Quinn NJ, Sacha GL, Wanek MR, et al. Determinants of vancomycin trough concentration in patients receiving continuous veno-venous hemodialysis[J]. Ann Pharmacother, 2022, 56(10): 1133-1138. DOI: 10.1177/10600280211073370. 79. Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring[J]. J Infect Chemother, 2013, 19(3): 365- 380. DOI: 10.1007/s10156-013-0599-4. 80. Kirwan M, Munshi R, O'Keeffe H, et al. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF)[J]. Crit Care, 2021, 25(1): 443. DOI: 10.1186/s13054-021-03863-4. 81. Charoensareerat T, Chaijamorn W, Boonpeng A, et al. Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: a Monte Carlo simulation study[J]. J Crit Care, 2019, 54: 77-82. DOI: 10.1016/j.jcrc.2019. 07.008. 82. Rybak MJ, Le J, Lodise T, et al. Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review of the american society of health-system pharmacists, the infectious diseases society of america, the pediatric infectious diseases society, and the society of infectious diseases pharmacists[J]. J Pediatric Infect Dis Soc, 2020, 9(3): 281- 284. DOI: 10.1093/jpids/piaa057. 83. Chen J, Li S, Wang Q, et al. Optimizing antimicrobial dosing for critically ill patients with MRSA infections: a new paradigm for improving efficacy during continuous renal replacement therapy[J]. Pharmaceutics, 2022, 14 (4): 842. DOI: 10.3390/pharmaceutics14040842. 84. Wang C, Chen J, Yang B, et al. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy[J]. Pharmacotherapy, 2023, 43(3): 180-188. DOI: 10.1002/phar.2771. 85. Thalhammer F, Rosenkranz AR, Burgmann H, et al. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes[J]. Wien Klin Wochenschr, 1997, 109(10): 362-365. 86. Shiraishi Y, Okajima M, Sai Y, et al. Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin[J]. Anaesth Intensive Care, 2012, 40(3): 442-449. DOI: 10.1177/0310057X1204000309. 87. Bellmann R, Falkensammer G, Seger C, et al. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration[J]. Int J Clin Pharmacol Ther, 2010, 48(4): 243-249. 88. Wolter K, Claus M, Fritschka E. Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD)[J]. Eur J Clin Pharmacol, 1994, 46(2): 179-180. DOI: 10.1007/BF00199886. 89. Ueda T, Takesue Y, Nakajima K, et al. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/ml in patients receiving continuous venovenous haemodiafiltration with a low flow rate[J]. J Infect Chemother, 2022, 28(2): 232- 237. DOI: 10.1016/j.jiac.2021.10.023. 90. Bastien O, Boulieu R, Bleyzac N, et al. Clinical use of ganciclovir during renal failure and continuous hemodialysis[J]. Intensive Care Med, 1994, 20(1): 47-48. DOI: 10.1007/BF02425056. 91. Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring[J]. J Antimicrob Chemother, 2022, 77(4): 869-879. DOI: 10.1093/jac/dkab499. 92. Preiswerk B, Rudiger A, Fehr J, et al. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy[J]. Infection, 2013, 41(2): 553-557. DOI: 10.1007/s15010-012-0300-3. 93. Corti N, Rudiger A, Chiesa A, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy[J]. Chemotherapy, 2013, 59(2): 143-151. DOI: 10.1159/000353400. 94. Xu X, Khadzhynov D, Peters H, et al. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy[J]. Br J Clin Pharmacol, 2017, 83(3): 498-509. DOI: 10.1111/bcp. 13131. 95. Xie F, Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy[J]. J Antimicrob Chemother, 2020, 75(6): 1559- 1566. DOI: 10.1093/jac/dkaa028. 96. Villa G, Di Maggio P, De Gaudio AR, et al. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review[J]. Crit Care, 2016, 20(1): 374. DOI: 10.1186/s13054-016-1551-7. 97. Barrasa H, Soraluce A, Isla A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment[J]. J Crit Care, 2019, 50: 69- 76. DOI: 10.1016/j.jcrc.2018.11.016. 98. Ide T, Takesue Y, Ikawa K, et al. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2018, 51(5): 745-751. DOI: 10.1016/j.ijantimicag.2018.01.021. 99. Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study[J]. Crit Care, 2018, 22(1): 341. DOI: 10.1186/s13054-018-2278-4. 100. Zhao HH, Tang WJ, Yang YX, et al. PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy[J]. Int J Clin Pharmacol Ther, 2020, 58(10): 531-538. DOI: 10.5414/CP203669. 101. Huang F, Cao WX, Yan YY, et al. Influence of continuous renal replacement therapy on the plasma concentration of tigecycline in patients with septic shock: a prospective observational study[J]. Front Pharmacol, 2023, 14: 1118788. DOI: 10.3389/fphar.2023.1118788. 102. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study[J]. J Antimicrob Chemother, 2012, 67(10): 2459-2462. DOI: 10.1093/jac/dks257. 103. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration [J]. Antimicrob Agents Chemother, 2005, 49(11): 4814- 4815. DOI: 10.1128/AAC.49.11.4814-4815.2005. 104. Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration[J]. Int J Antimicrob Agents, 2016, 48(3): 337-341. DOI: 10.1016/j.ijantimicag.2016.06.008. 105. Spapen H, van Laethem J, Hites M, et al. Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration[J]. J Transl Int Med, 2019, 7(3): 100-105. DOI: 10.2478/jtim-2019- 0022. 106. Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis[J]. J Antimicrob Chemother, 2013, 68(3): 674-677. DOI: 10.1093/jac/dks437. 107. Wang P, Xing H, Zhang F, et al. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration[J]. Int J Antimicrob Agents, 2022, 60(1): 106599. DOI: 10.1016/j.ijantimicag.2022.106599. 108. Pi MY, Cai CJ, Zuo LY, et al. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients[J]. J Antimicrob Chemother, 2023, 78(3): 792-801. DOI: 10.1093/jac/dkad012. 109. Hanafin PO, Kwa A, Zavascki AP, et al. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients[J]. Clin Microbiol Infect, 2023, 29(9): 1174-1181. DOI: 10.1016/j.cmi.2023.05.018. 110. Surovoy YA, Burkin MA, Galvidis IA, et al. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis[J]. Eur J Clin Pharmacol, 2023, 79(1): 79-87. DOI: 10.1007/s00228-022-03415-x. 111. Curkovic I, Lüthi B, Franzen D, et al. Trimethoprim/sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration[J]. Ann Pharmacother, 2010, 44(10): 1669-1672. DOI: 10. 1345/aph.1P160. 112. Kesner JM, Yardman-Frank JM, Mercier RC, et al. Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy[J]. Blood Purif, 2014, 38(3-4): 195-202. DOI: 10. 1159/000368884. 113. Oualha M, Tréluyer JM, Moshous D, et al. Fluconazole exposure in plasma and bile during continuous venovenous hemodialysis[J]. Ther Drug Monit, 2019, 41(4): 544-546. DOI: 10.1097/FTD.0000000000000641. 114. Lopez ND, Phillips KM. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration[J]. Pharmacotherapy, 2014, 34(9): e162-e168. DOI: 10.1002/phar.1470. 115. Patel K, Roberts JA, Lipman J, et al. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets[J]. Antimicrob Agents Chemother, 2011, 55(12): 5868-5873. DOI: 10.1128/AAC. 00424-11. 116. Sime FB, Stuart J, Butler J, et al. A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration[J]. Int J Antimicrob Agents, 2018, 52(4): 506-509. DOI: 10.1016/j.ijantimicag. 2018.07.008. 117. Kiser TH, Fish DN, Aquilante CL, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy[J]. Crit Care, 2015, 19(1): 32. DOI: 10.1186/s13054-015-0753-8. 118. Morris AA, Mueller SW, Rower JE, et al. Evaluation of sulfobutylether-β-cyclodextrin exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration[J]. Antimicrob Agents Chemother, 2015, 59(10): 6653-6656. DOI: 10.1128/AAC.01493-15. 119. Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2019, 63(12): e01085-19. DOI: 10. 1128/AAC.01085-19. 120. Vossen MG, Knafl D, Haidinger M, et al. Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients[J]. Antimicrob Agents Chemother, 2017, 61(8): e02425-16. DOI: 10. 1128/AAC.02425-16. 121. Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2013, 57(8): 4053-4057. DOI: 10.1128/AAC.00335-13. 122. Roger C, Wallis SC, Muller L, et al. Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration[J]. Clin Pharmacokinet, 2017, 56(9): 1057-1068. DOI: 10.1007/s40262-016-0495-z. 123. Honore PM, De Bels D, Attou R, et al. Adsorption and caspofungin dosing during continuous renal replacement therapy[J]. Crit Care, 2019, 23(1): 240. DOI: 10.1186/s13054-019-2526-2. 124. González de Molina F, Martínez-Alberici Mde L, Ferrer R. Treatment with echinocandins during continuous renal replacement therapy[J]. Crit Care, 2014, 18(2): 218. DOI: 10.1186/cc13803. 125. Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno- venous haemofiltration[J]. J Antimicrob Chemother, 2003, 51(3): 671-681. DOI: 10.1093/jac/dkg139. 126. Malone ME, Corrigan OI, Kavanagh PV, et al. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration[J]. Int J Antimicrob Agents, 2013, 42(4): 335-342. DOI: 10.1016/j.ijantimicag.2013.06.011. 127. Obata Y, Takazono T, Tashiro M, et al. Correction to: the clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study[J]. Clin Exp Nephrol, 2021, 25(3): 288. DOI: 10.1007/s10157-020-02004-5. 引用本文: 连续性肾替代治疗抗菌药物剂量调整共识专家组, 中国药学会医院药学专业委员会, 中国医药教育协会感染疾病专业委员会. 连续性肾替代治疗抗菌药物剂量调整专家共识(2024年版)[J]. 中华肾脏病杂志, 2024, 40(2): 158-174. DOI: 10.3760/cma.j.cn441217-20230906-00906. 文章编号:1001-7097(2024)02-0158-17 收稿日期:2023-09-06 出版日期:2024-02-15 网刊发布日期:2024-02-20 本文编辑:彭苗 |
|
来自: limingxin1969 > 《感染与抗感染》